Glucocorticosteroids in the Treatment of Inflammatory Bowel Disease and Approaches to Minimizing Systemic Activity

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2013 Mar 19

PMID 23503968

Citations 22

Authors

Cosimo Prantera

Stefano Marconi

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel diseases (IBDs) are a group of inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract. Reported prevalence is high in the United States and northern Europe, while the incidence varies greatly across the rest of Europe. Glucocorticosteroids are the standard treatment for IBD, but due to adverse events their use can be limited. However, new formulations of glucocorticosteroids have been developed to reduce systemic activation. The aim of this review was to assess and summarize the efficacy and safety of new formulations of glucocorticosteroids. A MEDLINE search identified publications focused on new formulations of nonsystemic steroid-based drugs for IBD and benefits and limitations of each of the new glucocorticosteroid formulations were identified. Budesonide has good efficacy and is an established treatment for Crohn's disease; it has been shown to be beneficial for the induction of remission in these patients, although it is not recommended for the maintenance of induced remission. Glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD. However, a recent study suggested that beclomethasone dipropionate may be effective for prolonged treatment in patients in the postacute phase of Crohn's disease who were treated with a short course of systemic steroids. The efficacy of fluticasone propionate and prednisolone metasulphobenzoate in IBD is not well established given the small number of patients enrolled in the few published clinical trials. While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted.

Citing Articles

Saffron as a Promising Therapy for Inflammatory Bowel Disease.

Rashid M, Rashid R, Saroya S, Deverapalli M, Brim H, Ashktorab H Nutrients. 2024; 16(14).

PMID: 39064796 PMC: 11280066. DOI: 10.3390/nu16142353.

Drug Repurposing in Crohn's Disease Using Danish Real-World Data.

Shakibfar S, Allin K, Jess T, Barbieri M, Battini V, Simoncic E Pragmat Obs Res. 2024; 15:17-29.

PMID: 38404739 PMC: 10894518. DOI: 10.2147/POR.S444569.

Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST" (Taper Or Abrupt Steroid STop) multicenter trial.

Komminoth M, Donath M, Hepprich M, Schuetz P, Blum C, Mueller B PLoS One. 2023; 18(4):e0281585.

PMID: 37018188 PMC: 10075434. DOI: 10.1371/journal.pone.0281585.

Patient-derived organoids for therapy personalization in inflammatory bowel diseases.

Lucafo M, Muzzo A, Marcuzzi M, Giorio L, Decorti G, Stocco G World J Gastroenterol. 2022; 28(24):2636-2653.

PMID: 35979165 PMC: 9260862. DOI: 10.3748/wjg.v28.i24.2636.

Review of exclusive enteral therapy in adult Crohn's disease.

Mitrev N, Huang H, Hannah B, Kariyawasam V BMJ Open Gastroenterol. 2021; 8(1).

PMID: 34580154 PMC: 8477235. DOI: 10.1136/bmjgast-2021-000745.

References

Darlow S, Mandal A, Pick B, Thomas T, Mayberry J, Robinson R . The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral density in acute ulcerative colitis. Eur J Gastroenterol Hepatol. 2004; 16(11):1173-6. DOI: 10.1097/00042737-200411000-00015. View

Mulder C, Fockens P, Meijer J, van der Heide H, Wiltink E, Tytgat G . Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996; 8(6):549-53. DOI: 10.1097/00042737-199606000-00010. View

Shivananda S, LENNARD-JONES J, Logan R, Fear N, Price A, Carpenter L . Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996; 39(5):690-7. PMC: 1383393. DOI: 10.1136/gut.39.5.690. View

Lindgren S, Lofberg R, Bergholm L, Hellblom M, Carling L, Ung K . Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol. 2002; 37(6):705-10. DOI: 10.1080/00365520212512. View

Simondi D, Pellicano R, Reggiani S, Pallavicino F, David E, Sguazzini C . A retrospective study on a cohort of patients with lymphocytic colitis. Rev Esp Enferm Dig. 2010; 102(6):381-4. DOI: 10.4321/s1130-01082010000600007. View

Geraghty J, Talbot I . Diversion colitis: histological features in the colon and rectum after defunctioning colostomy. Gut. 1991; 32(9):1020-3. PMC: 1379042. DOI: 10.1136/gut.32.9.1020. View

Gross V, Andus T, Ecker K, Raedler A, Loeschke K, Plauth M . Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut. 1998; 42(4):493-6. PMC: 1727061. DOI: 10.1136/gut.42.4.493. View

Papadakis K, Targan S . Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51:289-98. DOI: 10.1146/annurev.med.51.1.289. View

Tromm A, Bunganic I, Tomsova E, Tulassay Z, Lukas M, Kykal J . Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology. 2010; 140(2):425-434.e1. DOI: 10.1053/j.gastro.2010.11.004. View

10.

Biancone L, Gionchetti P, Del Vecchio Blanco G, Orlando A, Annese V, Papi C . Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis. 2007; 39(4):329-37. DOI: 10.1016/j.dld.2007.01.012. View

11.

Bernstein C, Fried M, Krabshuis J, Cohen H, Eliakim R, Fedail S . World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2009; 16(1):112-24. DOI: 10.1002/ibd.21048. View

12.

Mulder C, Endert E, van der Heide H, Houthoff H, Wiersinga W, Wiltink E . Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis. An adrenocortical approach. Neth J Med. 1989; 35(1-2):18-24. View

13.

van der Heide H, Tytgat G, Endert E, Wiltink E, Schipper M, Dekker W . Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol. 1988; 10(2):169-72. DOI: 10.1097/00004836-198804000-00013. View

14.

Seow C, Benchimol E, Griffiths A, Otley A, Steinhart A . Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008; (3):CD000296. DOI: 10.1002/14651858.CD000296.pub3. View

15.

Girlich C, Scholmerich J . Topical delivery of steroids in inflammatory bowel disease. Curr Drug Deliv. 2012; 9(4):345-9. DOI: 10.2174/156720112801323071. View

16.

Lichtenstein G, Bengtsson B, Hapten-White L, Rutgeerts P . Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther. 2008; 29(6):643-53. DOI: 10.1111/j.1365-2036.2008.03891.x. View

17.

Tremaine W, Hanauer S, Katz S, Winston B, Levine J, Persson T . Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002; 97(7):1748-54. DOI: 10.1111/j.1572-0241.2002.05835.x. View

18.

Lofberg R, Rutgeerts P, Malchow H, Lamers C, Danielsson A, Olaison G . Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996; 39(1):82-6. PMC: 1383237. DOI: 10.1136/gut.39.1.82. View

19.

Riley S, Gupta I, Mani V . A comparison of sucralfate and prednisolone enemas in the treatment of active distal ulcerative colitis. Scand J Gastroenterol. 1989; 24(8):1014-8. DOI: 10.3109/00365528909089249. View

20.

Cortot A, Colombel J, Rutgeerts P, Lauritsen K, Malchow H, Hamling J . Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut. 2001; 48(2):186-90. PMC: 1728198. DOI: 10.1136/gut.48.2.186. View